Science and business work in tandem to develop solid products for the mass market. Science, however, dictates following a standard set of principles so a standard repeatable product or result can be obtained. Standardizing this scientific method is a skill that is specialized and profitable as such. Companies that can offer this scientific skill set are companies that will likely become profitable as others recognize their value and need for its services.

Pacific Biometrics Inc., a clinical trial research services company, works to provide clinical trial, central library and contract research services to biotechnology and pharmaceutical companies. The company works in a variety of areas where protocols and central library services are needed for diabetes, cardiovascular disease, metabolic syndrome and other products research.

The pharmaceutical industry rises and falls based upon its pipeline of new drugs and research. Without a constant stream of new products to be put under patent, the multi-billion

Provectus Pharmaceuticals Inc. (PVCT.OB) is a Tennessee-based development stage pharmaceutical company that specializes in oncology and dermatology therapies. Complementing the company’s lineup of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.

In the biotechnology area, the company has developed groundbreaking technology to augment vaccine production and detect viruses. Another area that Provectus is focusing on is the dermatology space. The company is currently conducting Phase 2 clinical trials of their proprietary drug PH-10, to be used as a topical treatment for psoriasis and atopic dermatitis.

Provectus Pharma’s main focus however is in the treatment of cancer. The company is developing advanced therapies to target and destroy the deadliest cancers - melanoma, liver cancer, and breast cancer - while eliminating side effects. Clinical trials for treatment of metastatic melanoma and recurrent breast carcinoma with the company’s PV-10 drug are

Vanda Pharma (VNDA) and Titan Pharma (TTP) are a pair of biotech blow-ups which investors should avoid ahead of a July 27, 2008, PDUFA decision date for anti-psychotic drug Fanapta (iloperidone). Both stocks have lost about two-thirds of their market value over the last year and are down sharply recently on pipeline clinical trial failures. I don’t think the FDA will approve Fanapta as the anti-psychotic space already has plenty of similar options and thec agency is cracking down on the widespread, off-label use of these drugs in elderly patients.

According to the American Cancer Society, about 11,000 to 12,000 neuroendocrine tumors and neuroendocrine cancers are diagnosed each year in the United States. Carcinoid syndrome is a result of these tumors, which secret large amounts of serotonin that can cause severe diarrhea and abdominal discomfort. There are limited therapeutic options, and the gastrointestinal symptoms usually return over time, prompting biotechnology companies to discover new agents.

Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) is one such company looking to give patients symptomatic relief. The company today announced it has received Fast Track status from the U.S. Food and Drug Administration to accelerate the development of LX1032, an orally-delivered drug candidate for gastrointestinal symptoms associated with carcinoid syndrome.

“Fast Track status can accelerate the development and expedite the review of LX1032,” Arthur T. Sands, M.D., Ph.D., president and CEO of Lexicon stated in the press release. “The FDA recognizes the serious unmet medical need